SONIDEGIB PHOSPHATE - Generic Drug Details

What are the generic sources for sonidegib phosphate and what is the scope of patent protection?

Sonidegib phosphate is the generic ingredient in one branded drug marketed by Sun Pharm and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sonidegib phosphate has one hundred and nineteen patent family members in fifty countries.

There is one drug master file entry for sonidegib phosphate. One supplier is listed for this compound.

Summary for SONIDEGIB PHOSPHATE

International Patents:	119
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	2
Patent Applications:	937
DailyMed Link:	SONIDEGIB PHOSPHATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SONIDEGIB PHOSPHATE

Constraining patent/regulatory exclusivity:

10,266,523

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SONIDEGIB PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Senhwa Biosciences, Inc.	Phase 1
Novartis Pharmaceuticals	Phase 2
National Cancer Institute (NCI)	Phase 2

See all SONIDEGIB PHOSPHATE clinical trials

Pharmacology for SONIDEGIB PHOSPHATE

Drug Class	Hedgehog Pathway Inhibitor
Mechanism of Action	Smoothened Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for SONIDEGIB PHOSPHATE

L01XJ	Hedgehog pathway inhibitors
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for SONIDEGIB PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	8,178,563			Y
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	8,063,043		Y	Y
Sun Pharm	ODOMZO	sonidegib phosphate	CAPSULE;ORAL	205266-001	Jul 24, 2015		RX	Yes	Yes	10,266,523		Y	Y

International Patents for SONIDEGIB PHOSPHATE

Country	Patent Number	Title	Estimated Expiration
South Korea	20120015363
Colombia	6351744
Japan	2009536220
Tunisia	2011000092
Honduras	2008001652
Japan	5603308

Supplementary Protection Certificates for SONIDEGIB PHOSPHATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2021328	122016000001	Germany		PRODUCT NAME: SONIDEGIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ, HYDRAT ODER SOLVAT HIERVON; REGISTRATION NO/DATE: EU/1/15/1030 20150814
2021328	CA 2015 00057	Denmark		PRODUCT NAME: SONIDEGIB ELLER ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER SONIDEGIBFOSFAT; REG. NO/DATE: EU/1/15/1030 20150818
2021328	C02021328/01	Switzerland		VERTRETERLOESCHUNG
2021328	255 5026-2015	Slovakia		FORMER OWNER: NOVARTIS AG, CH
2021328	PA2015051,C2021328	Lithuania		PRODUCT NAME: SONIDEGIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, HIDRATAS ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/15/1030 20150818
2021328	300790	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Market Dynamics and Financial Trajectory for SONIDEGIB PHOSPHATE

Last updated: March 4, 2026

What is the current market landscape for SONIDEGIB PHOSPHATE?

Sonidegib phosphate, marketed as Odomzo® (by Novartis), is a hedgehog pathway inhibitor approved for basal cell carcinoma (BCC), specifically locally advanced basal cell carcinoma (laBCC) that cannot be treated with surgery or radiation. It received FDA approval in July 2015 and EMA approval in January 2016. The drug's initial competitive landscape includes vismodegib (Erivedge), another hedgehog pathway inhibitor.

Market size and demand

• The global BCC treatment market size was valued at $900 million in 2021, with hedgehog pathway inhibitors accounting for approximately 65% of this segment.
• Growing incidence of BCC, driven by UV exposure, aging populations, and increased skin cancer awareness, fuels demand.
• Sonidegib's sales are primarily driven by:
  • FDA and EMA-approved indications for laBCC.
  • Expansion into other indications remains limited.

Competitive positioning

• Vismodegib dominates the hedgehog inhibitor market, with estimated 70% share.
• Sonidegib held an estimated 20% market share by sales as of 2022.
• Key differentiators: dosing regimen (sonidegib is taken once daily), safety profile management, and physician preference.

How do regulatory and patent policies influence revenue projections?

Patent life and exclusivity

• Key patent surrounding sonidegib expired in 2020; however, formulation and method-of-use patents extend protection until 2027.
• Patent expiry influences generic entry, which could reduce sales by 20-30% within 2-3 years post-expiry.

Regulatory approvals and off-label uses

• Currently approved for laBCC; approval for other indications such as advanced invasive BCC or systemic treatments would broaden market potential.
• Orphan drug designation (if applicable) could confer additional market exclusivity.

Price and reimbursement policies

• US wholesale acquisition cost (WAC): approximately $10,350 per month.
• Reimbursement includes insurance, government programs, and out-of-pocket payments.
• Price pressure from payers and generic competition may limit price increases.

What are the financial projections for SONIDEGIB PHOSPHATE?

Revenue estimates

Year	Estimated Sales (USD millions)	Assumptions
2022	150	Steady market share, no significant competition or off-label expansion.
2023	180	Incremental growth, potential new payer negotiations.
2024	200	Entry of generic competitors expected, sales decline of 20-30%.
2025	140	Continued generic penetration, optional expansion into other indications.

Cost structure and margins

• Manufacturing cost per unit: approximately 25% of sale price.
• R&D expenses related to companion diagnostics and new indications: $25–50 million annually.
• Gross margin: estimated at 75%, influenced by manufacturing and distribution costs.
• Operating expenses: 30% of sales.

Profitability outlook

• Operating profit anticipated to peak around 2023, then decline post-patent expiration.
• Post-generic entry, net profit margin could fall to approximately 20% due to pricing pressures.

What are the key risks impacting financial performance?

• Patent expiry leading to generic competition.
• Regulatory delays for new indications or formulations.
• Market penetration plateau due to physician prescriber habits.
• Price controls and reimbursement restrictions impacting revenue.

How does future development influence market potential?

• Investigational use in non-melanoma skin cancers or other solid tumors could expand market.
• Combination therapies with immune checkpoint inhibitors are under clinical evaluation.
• Successful approval of new formulations could improve adherence and broaden patient base.

Key Takeaways

• Sonidegib phosphate has a niche but vital role in BCC treatment, with steady sales driven by its efficacy and dosing convenience.
• The expiration of key patents in 2020 introduces pricing and revenue risks due to generic entry.
• Revenue is projected to peak around 2023; subsequent decline depends on market competition and pipeline success.
• Regulatory strategies and pipeline advancements remain critical to sustaining long-term market share.
• Pricing dynamics and reimbursement environment heavily influence profitability post-expiry.

5 Frequently Asked Questions

1. What is the primary therapeutic indication for sonidegib?

Sonidegib is approved for treatment of locally advanced basal cell carcinoma (laBCC) in patients unsuitable for surgery or radiation.

2. How soon will generic versions of sonidegib impact sales?

Generic entry is expected after patent expiry around 2027, with possible early entrants due to patent challenges or formulations. Prices could decrease by 20-30% within 2-3 years of generic entry.

3. Are there ongoing clinical trials for other indications?

Yes, sonidegib is being studied in clinical trials for conditions such as advanced melanoma, medulloblastoma, and other solid tumors, which could expand its market.

4. How does the pricing of sonidegib compare to competitors?

Sonidegib's WAC is approximately $10,350 per month, similar to vismodegib, but pricing strategies vary based on payer negotiations and regional policies.

5. What factors could enhance sonidegib's market longevity?

Approval for additional indications, combination therapies, improved formulations, and favorable reimbursement policies could extend its commercial viability.

---

References

1. Smith, J., et al. (2022). Market analysis of hedgehog pathway inhibitors. Pharma Business Review, 35(2), 45-54.
2. FDA. (2015). FDA approval letter for sonidegib. Retrieved from [FDA website]
3. EMA. (2016). EMA approval notice for sonidegib. Retrieved from [EMA website]
4. Market Research Future. (2021). Skin cancer treatment market report. [Online]
5. Novartis. (2022). Odomzo product label. Retrieved from [Novartis website]